Asthma and Atopic Dermatitis in Asia, 1990–2021: The Global Burden of Disease Study 2021

特应性皮炎 哮喘 医学 疾病 皮肤病科 疾病负担 免疫学 病理
作者
GBD 2021 Asia Allergic Disorders Collaborators
出处
期刊:Clinical & Experimental Allergy [Wiley]
卷期号:55 (8): 671-690 被引量:6
标识
DOI:10.1111/cea.70024
摘要

BACKGROUND: Given the diverse population and regional differences across Asia, a comprehensive analysis of allergic diseases is crucial for guiding healthcare planning, resource allocation, and prevention strategies. Therefore, utilising the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021, we aimed to thoroughly investigate the burden of allergic conditions and their attributable risk factors in Asia. METHODS: Asthma and atopic dermatitis (AD) prevalence and burden estimates were calculated across various regions within Asia (Central, South, Southeast, East Asia and high-income Asia Pacific) from 1990 to 2021, covering age groups segmented into five-year intervals and analysing data separately and combined for males and females. The Bayesian meta-regression tool was employed to estimate the prevalence, incidence, and cause-specific mortality of allergic disorders. Asthma-related deaths and disability-adjusted life years (DALYs) attributable to each risk factor were estimated using relative risks, risk exposure and the theoretical minimum risk exposure level input. RESULTS: From 1990 to 2021, asthma in Asia showed significant declines in age-standardised prevalence, mortality, and DALYs, exceeding global trends. In 2021, an estimated 106 million (95% UI, 92-121) individuals in Asia had asthma, with age-standardised rates decreasing significantly. However, asthma-related deaths still accounted for 346,755 (278,046-464,848) cases in 2021. In contrast, the AD burden remained stable, with 68.1 million (65.4-71.0) cases in 2021, reflecting a 16.1% increase since 1990, though the age-standardised prevalence remained unchanged. AD exhibited the highest DALYs rates in high-income Asia Pacific and Central Asia, with significant gender disparities in prevalence. CONCLUSION: This study showed a declining age-standardised asthma burden, mortality, and impact, along with a stable burden of AD in Asia from 1990 to 2021. This comprehensive data analysis would provide invaluable insights for making targeted health interventions and policies aimed at mitigating the burden of allergic diseases in Asia.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Superman关注了科研通微信公众号
刚刚
强健的惜萍完成签到,获得积分20
刚刚
领导范儿的应助被zzc采纳,获得10
1秒前
1秒前
1秒前
1秒前
1秒前
灵巧飞飞完成签到,获得积分10
1秒前
2秒前
顾矜的应助被hu采纳,获得10
2秒前
3秒前
4秒前
所所的应助被zzz采纳,获得10
4秒前
liuqc发布了新的文献求助10
4秒前
HaidongZhang完成签到,获得积分10
4秒前
Jemmy完成签到,获得积分10
5秒前
5秒前
6秒前
7秒前
自信纸飞机完成签到,获得积分20
7秒前
7秒前
在水一方的应助被Mu采纳,获得10
7秒前
小十一发布了新的文献求助10
7秒前
8秒前
刁刁完成签到,获得积分10
8秒前
1234发布了新的文献求助10
8秒前
天道酬勤发布了新的文献求助10
9秒前
慕青的应助被诚心的小鸽子采纳,获得10
9秒前
英俊的铭的应助被孟寐以求采纳,获得20
9秒前
再长高一点吧完成签到,获得积分20
9秒前
10秒前
wan发布了新的文献求助10
10秒前
10秒前
依旧发布了新的文献求助10
10秒前
Hello的应助被麤七采纳,获得10
10秒前
11秒前
华仔的应助被空白采纳,获得10
11秒前
11秒前
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Oncology Clinical Trials: Successful Design, Conduct, and Analysis, Second Edition 800
Comprehensive Heterocyclic Chemistry IV 400
Qualitative Methodologies in Tourism Studies: Disrupting and Co-creating Critical Research 350
Représentation chimique de la structure des kérogènes et des asphaltènes en fonction de leur origine et de leur degré d'évolution 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8053063
求助须知:如何正确求助?哪些是违规求助? 9480474
关于积分的说明 21302820
捐赠科研通 7621209
什么是DOI,文献DOI怎么找? 3393907
关于科研通互助平台的介绍 2524942
邀请新用户注册赠送积分活动 2431991